ALLMedicine™ Ataxia Telangiectasia Center
Research & Reviews 596 results
Journal for Immunotherapy of Cancer; Wang Z, Zhang X et. al.
Jul 24th, 2021 - The efficacy of docetaxel-based chemotherapy is limited by the development of drug resistance. Recent studies demonstrated the efficacy of anti-programmed death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) immunotherapies in metastatic prostate...
Trends in Cancer; Ngoi NYL, Pham MM et. al.
Jul 3rd, 2021 - The replication stress response (RSR) involves a downstream kinase cascade comprising ataxia telangiectasia-mutated (ATM), ATM and rad3-related (ATR), checkpoint kinases 1 and 2 (CHK1/2), and WEE1-like protein kinase (WEE1), which cooperate to arr...
Nature Communications; Kirtay M, Sell J et. al.
Jul 2nd, 2021 - Ataxia Telangiectasia and Rad3-related (ATR) protein, as a key DNA damage response (DDR) regulator, plays an essential function in response to replication stress and controls cell viability. Hypomorphic mutations of ATR cause the human ATR-Seckel ...
Orphanet Journal of Rare Diseases; Tatfi M, Perthame E et. al.
Jun 29th, 2021 - Epstein-Barr virus (EBV) targets B-cells where it establishes a latent infection. EBV can transform B-cells in vitro and is recognized as an oncogenic virus, especially in the setting of immune compromise. Indeed, immunodeficient patients may fail...
Proceedings of the National Academy of Sciences of the Un... Zhu Q, Yang Q et. al.
Jun 2nd, 2021 - Ataxia telangiectasia and Rad3 related (ATR) activation after replication stress involves a cascade of reactions, including replication protein A (RPA) complex loading onto single-stranded DNA and ATR activator loading onto chromatin. The contribu...
Drugs 1 results see all →
Clinicaltrials.gov 8 results
Apr 13th, 2020 - PRIMARY OBJECTIVES: I. To define the recommended phase 2 dose (RP2D) of sirolimus combined with docetaxel and carboplatin in the treatment of metastatic castration resistant prostate cancer (CRPC). (Phase I) II. To assess the effectiveness of siro...
Mar 24th, 2020 - Metabolic syndrome is one of the most common disorders in industrialized countries. It consists of abnormal serum lipids, glucose intolerance, elevated blood pressure, and central obesity in the setting of insulin resistance. The syndrome substant...
Feb 16th, 2020 - Metabolic syndrome is one of the most common disorders in industrialized countries. It consists of abnormal serum lipids, glucose intolerance, elevated blood pressure, and central obesity in the setting of insulin resistance. The syndrome substant...
Jun 27th, 2019 - PRIMARY OBJECTIVES: I. To assess rate of 50% prostate-specific antigen (PSA) decline to docetaxel and carboplatin. SECONDARY OBJECTIVES: I. To assess PSA response duration to docetaxel and carboplatin. (Phase 2) II. To assess response of measurabl...
Nov 29th, 2017 - Ataxia teleangiectasia (A-T) is a rare devastating human recessive disorder characterized by progressive cerebellar ataxia, immunodeficiency, chromosomal instability and cancer susceptibility. The immunodeficiency is expressed by recurring infecti...
News 7 results
Apr 20th, 2021 - NEW YORK (Reuters Health) - Combining an ataxia telangiectasia and rad3-related (ATR) inhibitor with topoisomerase 1 (TOP1) yielded an objective response in more than a third of patients with small-cell lung cancer (SCLC) in a phase-2 proof-of-con...
Feb 24th, 2020 - The topoisomerase I (TOP1) inhibitor irinotecan could be effective in treating triple-negative breast cancer (TNBC), according to results from a preclinical study published in Science Translational Medicine. Florence Coussy, MD, PhD, of Institut C.
Jan 16th, 2018 - Johanna C. Bendell, MD The incidence of pancreas cancer continues to rise in many countries.1 In 2017, an estimated 53,600 cases were diagnosed in the United States, representing an approximately 45% increase over the past decade.2,3 Pancreatic du...
Oct 1st, 2016 - Longtime scientific advisors to the AT (Ataxia Telangiectasia) Children’s Project Nathaniel Heintz, PhD, and Michael Kastan, MD, PhD, have been elected to the National Academy of Sciences.
Mary Ann Moon
Aug 17th, 2015 - Adding olaparib to second-line paclitaxel therapy for recurrent or metastatic gastric adenocarcinoma improved overall survival but not progression-free survival in a phase II clinical trial, investigators reported online Aug. 17 in Journal of Clin.